<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05004519</url>
  </required_header>
  <id_info>
    <org_study_id>P2021/378</org_study_id>
    <nct_id>NCT05004519</nct_id>
  </id_info>
  <brief_title>Benefits of Opioid Free Anesthesia on Morphine Consumption in Gastric Bypass</brief_title>
  <official_title>Impact of an Opioid Free Anesthesia Protocol Compared to Multimodal Anesthesia on Postoperative Morphine Consumption in an Enhanced Recovery After Gastric Bypass Surgery Protocol: a Prospective, Double Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>matthieu clanet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chirec</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Opioid free anesthesia is a recent anesthesia technique with the aim to avoid peroperative&#xD;
      use of morphinics to allow a diminution of secondary morphinics effects in the postoperative&#xD;
      period.&#xD;
&#xD;
      There is no robust data on the real benefits of such procedures. Obese patients are&#xD;
      particular at risk of secondary effects of opioids. The aim of our study is to compare opioid&#xD;
      free anesthesia to multimodal anesthesia on postoperative morphine consumption after a&#xD;
      laparoscopic gastric bypass.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to study the impact of an opioid free anesthesia protocol on the&#xD;
      postoperative morphine consumption in laparoscopic gastric bypass compared to a multimodal&#xD;
      anesthesia protocol.&#xD;
&#xD;
      200 morbidly obese patients (Body mass index &gt;40Kg/m2 or &gt;35kg/m2 AND/OR diabete mellitus&#xD;
      AND/OR sleep apnea syndrome AND/OR arterial hypertension.&#xD;
&#xD;
      A randomization will allocate two groups of 100 patients in:&#xD;
&#xD;
        -  Group 1: Multimodal anesthesia without opioids&#xD;
&#xD;
        -  Group 2: Multimodal anesthesia with opioid sparing The patient, the anesthésist and the&#xD;
           data evaluator will be blinded about the allocation of the patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Morphine consumption</measure>
    <time_frame>24 hours after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual analog scale</measure>
    <time_frame>Post Anesthesia Care Unit admission (Hour 0), Hour +4, Hour +24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine consumption</measure>
    <time_frame>Post Anesthesia Care Unit admission (Hour 0), Hour +4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Recovery 40 score</measure>
    <time_frame>operative Day -1, Operative day +1, operative day +30</time_frame>
    <description>Recovery scale: From 40 (worst recovery) to 200 (Best Recovery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoxemia</measure>
    <time_frame>up to patient discharge</time_frame>
    <description>SpO2 &lt; 90% on 2 liters of nasal Oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Nausea and vomiting</measure>
    <time_frame>Post Anesthesia Care Unit admission (Hour 0), Hour +4, Hour +24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to obtain Aldrete score &gt;9</measure>
    <time_frame>Up to Postanesthesia care unit discharge</time_frame>
    <description>Scale from 0 (worst) to 10 (Best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of Antiemetics</measure>
    <time_frame>Up to patient discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bradycardia and use of atropine</measure>
    <time_frame>Up to patient discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Alveolar Concentration to obtain sedline 30-50</measure>
    <time_frame>during surgery</time_frame>
    <description>Sedline (MassimoTM) is a tool to assess the depth of anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nociception level index</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to obtain discharge criteria</measure>
    <time_frame>up to patient discharge</time_frame>
    <description>in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clavien Dindo Scale</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Postoperative complication from Grade 1 (no intervention) to 5 (death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmissions rate</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Admission of the patient in hospital during the first 30 postoperative days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Analgesics, Opioid</condition>
  <arm_group>
    <arm_group_label>Opioid free anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 0,5 microgrammes/kg of ideal body weight (IBW) + magnesium 40 mg/kg of total body weight (TBW) in 10 minutes&#xD;
Dexmedetomidine 0,4- 0,8 microgrammes/kg of IBW/h;Lidocaine 2% 49ml+ Ketamine 50mg: 1ml/10kg of IBW/ hour;Ketamine 25 mg;lidocaïne 1,5 mg/kg IBW;Propofol 2mg/kgTBW;Rocuronium 1,2 mg/kg IBW;Cefazoline 2g if &gt;120 kg, 3g if &gt;120Kg;Paracetamol 15 mg/ KgTBW;Diclofenac 75 mg;Dexamethasone 10 mg;Ondansetron 4 mg;Sevorane;dexmedetomidine: 0,4-0,8 microgramme/kg/h;Rocuronium 0,1 mg/kg of IBW if posttetanic count&gt;1/10;Atropine 0,5 mg if heart rate &lt; 40/min;Ephedrine 5mg in Arterial mean pressure &lt; 20% of basal value;Nicardipine 0,5 mg if Arterial mean pressure &gt; 20% of basal value Emergence&#xD;
Stop dexmedetomidine;Stop sevorane;1 ml of NaCL 0,9%;Suggamadex 4 mg/ kg of IBW+ 4mg/kg of 40% ABW Post-anesthesia:Lidocaïne 2% 49ml + Ketamine 50 mg: 0,5 ml/ 10 kg IBW;Paracetamol 1g/6h;Diclofenac 75mg/12h;Morphine patient controlled analgesia: 1 mg/5 min, maximum 20mg/ 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multimodal anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>magnesium 40 mg/kg of total body weight (TBW) in 10 minutes&#xD;
Remifentanil 0,2-0,4 microgrammes/kg/min of ideal body weight; Saline 0,9%: Infusion at 1ml/10kg of ideal body weight/ hour;Ketamine 25 mg;lidocaïne 1,5 mg/kg IBW;Propofol 2mg/kgTBW;Rocuronium 1,2 mg/kg IBW;Cefazoline 2g if &gt;120 kg, 3g if &gt;120Kg;Paracetamol 15 mg/ Kg TBW;Diclofenac 75 mg;Dexamethasone 10 mg;Ondansetron 4 mg;Sevorane;remifentanil 0,2-0,4 microgrammes/kg/min;Rocuronium 0,1 mg/kg of IBW if posttetanic count&gt;1/10;Atropine 0,5 mg if heart rate &lt; 40/min;Ephedrine 5mg in Arterial mean pressure &lt; 20% of basal value;Nicardipine 0,5 mg if Arterial mean pressure &gt; 20% of basal value Emergence&#xD;
Stop remifentanil;Stop sevorane;1 ml of morphine 10mg/ml;Suggamadex 4 mg/ kg of IBW+ 4mg/kg of 40% ABW Post-anesthesia:Salne 50ml: 0,5 ml/ 10 kg IBW;Paracetamol 1g/6h;Diclofenac 75mg/12h;Morphine patient controlled analgesia: 1 mg/5 min, maximum 20mg/ 4 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Injection [Precedex]</intervention_name>
    <description>dexmedetomidine or remifentanil during laparoscopic gastric bypass</description>
    <arm_group_label>Opioid free anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>dexmedetomidine or remifentanil during laparoscopic gastric bypass</description>
    <arm_group_label>Multimodal anesthesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of anesthesia score (ASA) 2-3&#xD;
&#xD;
          -  Scheduled for a laparoscopic gastric bypass&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal&#xD;
&#xD;
          -  Medical diseases: Cardiac arrhythmia like atrioventricular block 2nd or 3rd degree,&#xD;
             pacemaker, arterial hypotension, severe bradycardia, cerebrovascular pathology, renal&#xD;
             and/or hepatic insufficiency&#xD;
&#xD;
          -  Previous bariatric surgery&#xD;
&#xD;
          -  Allergy to any medication used during the surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthieu CLANET, MD</last_name>
    <phone>+32497643671</phone>
    <email>matthieuclanet@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karim TOUIHRI, MD</last_name>
    <phone>+32484933323</phone>
    <email>katouihri@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHIREC Delta Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1160</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>matthieu CLANET, MD</last_name>
      <phone>+32497643671</phone>
      <email>matthieuclanet@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Karim TOUIHRI, MD</last_name>
      <phone>+32484933323</phone>
      <email>katouihri@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chirec</investigator_affiliation>
    <investigator_full_name>matthieu clanet</investigator_full_name>
    <investigator_title>Head of anesthesia department</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Study protocol, informed consent form</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

